The transient effect of Fas-FasL pathway activation on T cells in a graft-versus-host disease (GvHD) model was improved by overexpressing FasL on MSCs in vitro and in vivo, suggesting an interesting therapeutic strategy for the treatment of GvHD [75, 76]. This evidence concerns the gene FASLG and graft versus host disease.